Toyomasa Katagiri
Direktor/Vorstandsmitglied bei Cancer Precision Medicine KK
Ursprung des Netzwerks ersten Grades von Toyomasa Katagiri
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
| Public Company | Biotechnology | 9 | |
Immunas Pharma, Inc.
 Immunas Pharma, Inc. Pharmaceuticals: MajorHealth Technology Immunas Pharma, Inc. develops anti-cancer antibody medicines. The company is based in Kawasaki, Japan. Immunas Pharma was acquired by OncoTherapy Science, Inc. on September 30, 2007 for $0.43 million.
4
| Holding Company | Pharmaceuticals: Major | 4 |
Cancer Precision Medicine KK
1
| Private Company | 1 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Toyomasa Katagiri
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| Laboratoires OncoTherapy Science France SARL | Director/Board Member Corporate Officer/Principal | ||
Dojin Iyaku-Kako Co., Ltd.
 Dojin Iyaku-Kako Co., Ltd. Pharmaceuticals: MajorHealth Technology Dojin Iyaku-Kaku Co., Ltd. is engaged in the development, production, and distribution of pharmaceutical products and pharmaceutical raw materials. The company was established in 1946 and is based in Tokyo, Japan. | Pharmaceuticals: Major | President | |
| Iwate Medical University | College/University | Undergraduate Degree | |
G&G Science Co., Ltd.
 G&G Science Co., Ltd. Miscellaneous Commercial ServicesCommercial Services G&G Science Co., Ltd. provides research and development services for DNA analysis and consulting. The private company is based in Fukushima, Japan. | Miscellaneous Commercial Services | Comptroller/Controller/Auditor | |
| SUN-LIFE HOLDING CO.,LTD. | Other Consumer Services | Director/Board Member | |
| Sun Life Members Co., Ltd. | Comptroller/Controller/Auditor | ||
| Seoul National University College of Veterinary Medicine | College/University | Undergraduate Degree | |
| Seoul National University | College/University | Graduate Degree | |
| University of Tokyo | College/University | Doctorate Degree | |
HanaVax, Inc.
 HanaVax, Inc. BiotechnologyHealth Technology HanaVax, Inc. develops nasal vaccine against infectious diseases. It develops pneumococcal nasal vaccine to prevent pneumonia, sepsis and otitis media. The company was founded by Hosei Ou on December 27, 2017 and is headquartered in Tokyo, Japan. | Biotechnology | Comptroller/Controller/Auditor |
Statistik
International
| Japan | 8 |
| Südkorea | 3 |
| Frankreich | 2 |
Sektoral
| Consumer Services | 6 |
| Health Technology | 3 |
| Commercial Services | 2 |
Operativ
| Director/Board Member | 17 |
| President | 8 |
| Comptroller/Controller/Auditor | 6 |
| Chief Tech/Sci/R&D Officer | 5 |
| Corporate Officer/Principal | 5 |
Am stärksten vernetzte Beziehungen
- Börse
- Insiders
- Toyomasa Katagiri
- Unternehmensverbindungen
